Philip Morris International IncChange company Symbol lookupSelect an option...PM Philip Morris International IncGVYB Golden Valley BankDHC Diversified Healthcare TrustMGNI Magnite IncINFN Infinera CorpPRSRW Prospector Capital Equity Warrants 1st Jan 2025 *W EXP 01/01/2025HYMCW Hycroft Mining Holding Equity Warrant Exp 29th May 2025 *W EXP 05/29/2025NVOS Novo Integrated Sciences IncTEL TE Connectivity LtdNOTV Inotiv IncGo
Philip Morris International Inc. (PMI) is an international tobacco company. It focuses on delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. Its product portfolio consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. It is engaged in developing smoke-free products for adults along with building scientific assessment capabilities in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The United States Food and Drug Administration (FDA) has authorized versions of its IQOS Platform 1 device and consumables, and Swedish Match's General snus, as Modified Risk Tobacco Products (MRTPs). Its portfolio consists of both international and local brands and is led by Marlboro. Its other cigarette brands include Chesterfield, L&M and Philip Morris.
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
PM's position in the Tobacco industry
| Industry Peers | MO | XXII | |
|---|---|---|---|
Summary | |||
| Company Profile | Philip Morris International Inc. (PMI) is an international tobacco company. It focuses on delivering a smoke-free future and evolving its portfolio for the long term to include products outside of... | Altria Group, Inc. is a holding company that provides a portfolio of tobacco products for United States tobacco consumers aged 21+. The Company operates through two segments: smokeable tobacco... Go to MO summary | 22nd Century Group, Inc. is an agricultural biotechnology and intellectual property company. The Company is focused on utilizing advanced alkaloid plant technologies to improve health and wellness... Go to XXII summary |
| 52-Week Change | VS. INDUSTRY | -16.66% | -65.04% |
| Market Cap | VS. INDUSTRY | $79.7B | $143.9M |
| Beta | VS. INDUSTRY | 0.6 | 1.8 |
| Dividend Yield | VS. INDUSTRY | 8.42% | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 14.35x | -- |
| Data as of | |||
Fundamentals | |||
| Total Revenue (TTM) | VS. INDUSTRY | $24.9B | $75.0M |
| Profit Margin | VS. INDUSTRY | 22.44% | -92.05% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -2.19% | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | -3.66% | 126.08% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.